Entos Pharmaceuticals and Lilly Pharmaceuticals have signed a research and collaboration agreement
Lilly and Entos Pharmaceuticals have signed a research and collaboration agreement to help develop innovative therapies for a variety of neurologic conditions.
The combination of Entos’ Fusogenix nucleic acid delivery technology with Lilly’s therapeutic payload has the potential to solve a major problem in the delivery of nucleic acid medicines to the nervous system.
The businesses announced today that Eli Lilly and Company has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology for research, development, and commercialization of nucleic acid medicines aimed at the central and peripheral nervous systems. Lilly will be able to use this technology to gain access to a unique delivery platform that has the potential to tackle a key delivery barrier for numerous nucleic acid therapeutic modalities.
Lilly and Entos have agreed to numerous programs focused on the development of proteo-lipid vehicles (PLV) for the transport of therapeutic cargo supplied by Lilly to targets in the central and peripheral nervous systems under the terms of the research and partnership agreement. Using its patented Fusogenix platform technology, Entos will be in charge of the generation, development, and optimization of PLVs.
“Nucleic acid-based therapies hold great promise in addressing the biologic cause of many serious diseases that have a significant unmet medical need. Overcoming barriers to the safe and effective delivery of such therapies to specific target cells is essential to realizing their potential. We look forward to working with Entos as part of our efforts to overcome this challenge and develop potential new therapies that may improve patient outcomes,”said Andrew Adams, vice president, Lilly Genetic Medicine.
“For more than 145 years, Lilly has demonstrated its ability to incorporate cutting-edge scientific advances into drug development strategies. We are excited for the opportunity to play a part in Lilly’s ongoing quest to develop high-quality medicines and believe our collaboration with Lilly is an important validation of the potential value of our expertise and technology platform,” said John Lewis, Ph.D., founder, and CEO of Entos.
Lilly will be in charge of choosing PLVs for clinical trials and commercialization. Entos will get a $50 million upfront payment, which includes Lilly’s equity investment in the company. Entos is also eligible to receive up to $400 million in future developmental and commercial milestone payments, as well as royalties, based on the successful development and commercialization of each of the collaboration’s products.
According to Generally Accepted Accounting Principles, this transaction will be included in Lilly’s reported results and financial forecasts (GAAP). As a result of this acquisition, Lilly’s non-GAAP earnings per share guidance for 2021 and 2022 will remain unchanged.